To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicel 300 mg Capsule Fed Conditions

This study has been completed.
Information provided by:
Sandoz Identifier:
First received: April 14, 2009
Last updated: April 15, 2009
Last verified: April 2009

To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fed conditions.

Condition Intervention Phase
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Center, Open, Randomized, 2-Way, 2-Period, 2-Sequence Crossover Study of the Bioequivalence of 300 mg Cefdinir (Test Formulation) and Omnicel 300 mg Capsule (Reference Formulation) Each Given as a Single Oral Dose to Twenty-Eight Healthy Male and/or Female Volunteers in the Fed State

Resource links provided by NLM:

Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Enrollment: 28
Study Start Date: April 2005
Study Completion Date: April 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cefdinir 300 mg Capsule (Sandoz, Austria)
Drug: Cefdinir 300 mg Capsule (Sandoz, Austria)
Active Comparator: 2
Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)
Drug: Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)


Ages Eligible for Study:   18 Years to 56 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Please refer to this study by its identifier: NCT00882154

Sponsors and Collaborators
Sandoz Inc.
Principal Investigator: Richard Larouche, M.D. SFBC Anapharm
  More Information

No publications provided

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc. Identifier: NCT00882154     History of Changes
Other Study ID Numbers: 50039
Study First Received: April 14, 2009
Last Updated: April 15, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Sandoz:

Additional relevant MeSH terms:
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions processed this record on April 17, 2014